Jun 16, 2020
Biohaven Presents NURTEC(TM) (rimegepant) Clinical and Pharmacoeconomic Data at the American Headache Society (AHS) Virtual Annual Scientific Meeting
Jun 15, 2020
AbbVie to Showcase 27 Studies at the Virtual 2020 Annual Scientific Meeting of the American Headache Society
May 07, 2020
Biohaven Pharmaceuticals Reports First Quarter 2020 Financial Results and Recent Business Developments
Apr 07, 2020
Frontiers in Neurology Publishes Study Evaluating Remote Electrical Neuromodulation (REN) As Viable Alternative to Drugs for Acute Migraine
Apr 07, 2020
Biohaven Enters Into Collaboration With Cove, Leading Migraine Telemedicine Platform, To Enhance Accessibility Of NURTEC(TM) ODT
Apr 02, 2020
COVID-19 Pandemic in the US May Curtail Uptake of Recent Acute Migraine Market Entrants, Diminishing Specialists' Prelaunch Expectations that Biohaven's Nurtec ODT Would Challenge Allergan's Ubrelvy and Eli Lilly's Reyvow
Mar 30, 2020
Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC(TM), Dosed Every Other Day, for the Preventive Treatment of Migraine
Mar 23, 2020
Biohaven to Advance Vazegepant into Phase 3 for the Acute Treatment of Migraine Following Successful End of Phase 2 Meeting with FDA
Mar 13, 2020
Biohaven Announces Patient Savings Program Where Patients Can Pay as Little as $0 for NURTEC(TM) ODT (rimegepant 75 mg) for the Acute Treatment of Migraine in Adults
Feb 27, 2020
Biohaven's NURTEC(TM) ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults
Feb 10, 2020
Biohaven's Rimegepant Named To Cortellis 2020 Potential Blockbuster "Drugs to Watch" List
Dec 17, 2019
Biohaven Achieves Positive Topline Results in Pivotal Phase 2/3 Study of Vazegepant, The First and Only Intranasal CGRP Receptor Antagonist in Clinical Development for the Acute Treatment of Migraine
Dec 03, 2019
Theranica: Journal of Expert Review of Medical Devices Publishes Profile of Nerivio(TM)
Nov 20, 2019
Impel NeuroPharma Announces Publication Of Narrative Review In The Journal Headache Supporting Need For Novel Formulations Of Dihydroergotamine (DHE) In Addressing Acute Treatment Of Migraine
Oct 17, 2019
Prime Therapeutics Study Finds Use, Costs for New Migraine Prevention Medications Projected to Triple by 2020
Oct 02, 2019
Upsher-Smith Laboratories Launches Tosymra(TM) (sumatriptan) Nasal Spray For The Acute Treatment Of Migraine In Adults
Sep 10, 2019
Biohaven Advances NOJECTION(TM) Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine
Sep 05, 2019
Impel NeuroPharma to Present Data From INP104 Clinical Program at the 19th Congress of the International Headache Society
Sep 03, 2019
Impel NeuroPharma Announces Last Patient Enrolled In Phase 3 Trial Evaluating INP104 For The Treatment Of Acute Migraine
Sep 03, 2019
Global Migraine Drugs Market Report 2019: Analysis (2009-2018) & Outlook (2019-2025)